Elsevier

Psychiatry Research

Volume 227, Issues 2–3, 30 June 2015, Pages 278-282
Psychiatry Research

Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia

https://doi.org/10.1016/j.psychres.2015.02.021Get rights and content

Highlights

  • Dopamine supersensitivity psychosis (DSP) in schizophrenia is characterized by unstable psychosis and/or tardive dyskinesia (TD).

  • The development of DSP is promoted by long-term antipsychotic treatment.

  • We investigated the role of DSP in treatment-resistant schizophrenia (TRS) which shows both a lesser response to and intolerance to pharmacotherapy.

  • Approximately 70% of the patients in our TRS cohort had experienced at least a single DSP episode at some point during treatment.

  • This finding strongly suggests that these DSP may play an important role in the process leading to treatment refractoriness in schizophrenia.

Abstract

There may be subtypes in treatment-resistant schizophrenia (TRS), and one of the subtypes may be related to dopamine supersensitivity psychosis (DSP). In developing strategies for prevention and treatment TRS, it is important to clarify the role of DSP in TRS. TRS patients were recruited from 3 hospitals for the present study. Through chart reviews, all patients were judged as either TRS or not, and then possible TRS patients were investigated about their past/present histories of DSP episode(s) by direct interviews. We then compared each factor between the groups with and without DSP episode(s). Out of 611 patients screened, 147 patients met the criteria for TRS and were included in the present analysis. These were divided into groups with and without DSP, comprising 106 (72.1%) and 41 patients (27.9%), respectively. Clinical characteristics in the two groups were similar, except for drug-induced movement disorders (DIMDs), which were significantly more important in DSP patients. Of the DSP patients, 42% and 56% experienced rebound psychosis and tolerance to antipsychotic effects, respectively. The present study revealed that approximately 70% of TRS patients experienced one or more DSP episodes, which may have a strong impact on the long-term prognosis of patients with schizophrenia.

Introduction

Although pharmacotherapy with antipsychotics has been a main strategy in treating schizophrenia, only 30–45% of patients experience and adequate response to these drugs (Andreasen et al., 2005, Bertelsen et al., 2009). Patients who respond poorly to treatment with two or more antipsychotic drugs are diagnosed as treatment-resistant schizophrenia (TRS) (Kane et al., 1988, Brenner et al., 1990). Clozapine has been established as the only effective agent for treatment-resistant cases, but some patients poorly respond even to this drug (Chakos et al., 2001, Henna Neto and Elkis, 2007). These data suggest the existence of subtypes in TRS and the importance of clarifying these subtypes in developing strategies for the prevention and treatment of schizophrenia.

One possible type of TRS may be related to antipsychotic-induced dopamine supersensitivity psychosis (DSP), which was first reported by Chouinard et al. (1978) and was recently classified as iatrogenic supersensitivity psychosis (Iyo et al., 2013, Seeman and Seeman, 2013). DSP is considered to develop following increases in antipsychotic dosages accompanying with relapses in patients with schizophrenia, although we should also take account of natural deterioration as a feature of schizophrenia. They progressively may show severer positive symptoms and need higher doses of antipsychotics, reaching TRS. Possible clinical features of this psychosis are co-existence of tardive dyskinesia (TD), relapse episodes immediately following treatment discontinuation (rebound psychosis) and/or developed tolerance to the drugs׳ antipsychotic effects despite continuous treatment (Chouinard, 1991, Moncrieff, 2006).

We recently proposed possible mechanisms underlying DSP and methods for the prevention and treatment of DSP on the basis of dopamine D2 receptor (DRD2) up-regulation (Iyo et al., 2013). In addition, antipsychotic-induced dopamine supersensitivity can be caused not only by an elevation in DRD2, but also by an increase in dopamine D2High receptors, which are known to represent the functional high-affinity state of the DRD2 (Seeman et al., 2005). Briefly, patients with DSP have an up-regulation and increasing supersensitivity of brain DRD2 induced by long-term over-blockade by antipsychotics and need higher dosages of antipsychotics to suppress the excessive dopamine neurotransmission via the increased DRD2. Higher antipsychotic dosages may yield higher fluctuation in the antipsychotic levels in the body since the elimination half-life from the body may be almost same regardless different dosages, leading to unstable psychotic symptoms. We hypothesized that an antipsychotic drug with a longer elimination half-life, which provides a stable plasma level, would produce a stable and optimal DRD2 blockade. Indeed, we reported that risperidone long-acting injectable form (LAI) combined with ongoing oral antipsychotics, which were gradually reduced to achieve maximal clinical effects with minimal side effects, improved refractory psychotic symptoms in the TRS patients with DSP significantly greater than those without DSP (Kimura et al., 2013, Kimura et al., 2014). It is suggested that there may be at least two types of TRS from the viewpoint of response to LAI, i.e., DSP and non-DSP. Therefore, it is important to further clarify subtypes in TRS, especially to explore the contributing roles of DSP.

The present study aims to compare the clinical characteristics of TRS between patients with and without DSP by examining the history of their symptoms, and to clarify the roles of DSP in TRS.

Section snippets

Subjects

The present study was conducted in three psychiatric hospitals. The study protocol was approved by the ethics committees of all relevant facilities and was conducted in accordance with the Helsinki declaration. All 611 patients diagnosed as having schizophrenia or schizoaffective disorder (DSM-IV-TR) in either the outpatient or inpatient divisions of the research facilities were screened as candidate participants, by investigation of medical charts. Among them, a total of 202 patients were

Results

All 611 patients in the research facilities were screened; among them, 147 TRS patients were included in the final analysis (Fig. 1).

Of the TRS patients, 106 (72.1%) were judged as having a history of DSP according to the criteria (Table 2). There were no significant differences in demographical indexes between the groups with and without DSP episodes (P>0.05). Furthermore, no difference in BPRS total score, positive symptoms, GAF or CGI-S was observed between the groups. Negative symptoms in

Discussion

The present study demonstrated that patients with DSP related to antipsychotic treatment comprised about 70% of the TRS patient group. There were no significant differences in most of the clinical characteristics at the current interview between the patient groups with and without DSP, but the patients with DSP showed greater severities in EPS than those without DSP, which did not essentially differ between analysis including and excluding TD. These suggest that DSP is an important subtype of

Contributors

Study concept and design: Kanahara, Iyo.

Acquisition of data: Suzuki, Kanahara, Yamanaka, Takase, Oda, Kimura.

Analysis and interpretation of data: Suzuki, Kanahara.

Drafting of the manuscript: Suzuki, Kanahara, Iyo.

Obtained funding: Kanahara.

Study supervision: Watanabe, Iyo.

Conflict of interest

Dr. Kanahara received grant funding from Ministry of Health, Labor and Welfare and SENSHIN Medical Research Foundation and reported honoraria from Eli Lilly, Otsuka and Janssen. Dr. Yamanaka reported honoraria from Otsuka, Dainippon Sumitomo, Janssen and Eli Lilly. Dr. Kimura reported honoraria from AstraZeneca, Janssen, Eli Lilly, Meiji Seika, Otsuka and Mochida. Dr. Watanabe reported honoraria from Eli Lilly, Dainippon Sumitomo, Astellas, GlaxoSmithKline, Mochida and Eisai. Dr. Iyo received

Acknowledgment

This study is supported by SENSHIN Medical Research Foundation in Japan (Heisei25-Ippan).

References (33)

  • N.C. Andreasen et al.

    Remission in schizophrenia: proposed criteria and rationale for consensus

    American Journal of Psychiatry

    (2005)
  • H.D. Brenner et al.

    Defining treatment refractoriness in schizophrenia

    Schizophrenia Bulletin

    (1990)
  • W.T. Carpenter et al.

    Deficit and nondeficit forms of schizophrenia: the concept

    American Journal of Psychiatry

    (1988)
  • M. Chakos et al.

    Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

    American Journal of Psychiatry

    (2001)
  • G. Chouinard et al.

    Neuroleptic-induced supersensitivity psychosis

    American Journal of Psychiatry

    (1978)
  • G. Chouinard et al.

    A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases

    Journal of Clinical Psychopharmacology

    (1988)
  • Cited by (65)

    • The effects of cumulative antipsychotic dose on brain structures in patients with schizophrenia: Observational study of multiple CT scans over a long-term clinical course

      2022, Psychiatry Research - Neuroimaging
      Citation Excerpt :

      In terms of the pharmacological difference between typical and atypical antipsychotics, typical antipsychotics, especially over the long term, promote the development of dopamine supersensitivity (DS) at dopamine D2 receptors (Chouinard, 1991; Iyo et al., 2013). This state is directly linked to repeated relapses of psychosis and novel/severe positive symptoms, leading to a treatment-resistant state (Suzuki et al., 2015; Oda et al., 2015). The finding of a long-term follow-up project that relapse duration (from psychotic relapse to its improvement) was significantly correlated with brain volume reduction (Andreasen et al., 2013) might at least partly explain the psychosis relapse and novel/severe positive symptoms in patients with DS, since relapses in patients with DS often require more time to control.

    • Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats

      2021, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      It is thus conceivable that various factors other than dopamine signaling (e.g., serotonin, glutamate, and neurotensin) are also involved in the development of DSP. It has been estimated that as many as 50%–70% of patients with TRS have DSP episodes (Chouinard and Chouinard, 2008; Suzuki et al., 2015). It is thus likely that DSP contributes significantly to treatment resistance among individuals with schizophrenia.

    View all citing articles on Scopus
    View full text